See every side of every news story
Published loading...Updated

Patients scramble as cheaper obesity drug alternatives disappear

  • Cheaper alternatives to weight-loss drugs like Wegovy and Zepbound are becoming unavailable, leading some patients to seek compounded versions at pharmacies and telehealth companies.
  • The FDA has announced that restrictions on compounded versions of tirzepatide and semaglutide will take effect on April 22 and May 22, respectively, impacting many Americans.
  • A federal judge denied the request to challenge the FDA's restrictions, stating that compounded drugs lack FDA approval for safety and effectiveness.
  • Patients across the U.S. Express concern about losing access to affordable medication, with one stating, 'If I don’t have this medicine available to me, I will 100% gain weight.
Insights by Ground AI
Does this summary seem wrong?

9 Articles

All
Left
1
Center
4
Right
2
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 57% of the sources are Center
57% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Newsday broke the news in United States on Wednesday, March 19, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.